Uvax Bio

Uvax Bio

Biotechnology, 660 W Germantown Pike, Newark, Delaware, 19462, United States, 11-50 Employees

uvaxbio.com

  • LinkedIn

Who is UVAX BIO

Founded in early 2018, Uvax Bio, a spin-off vaccine company from Scripps Research, La Jolla, CA, employs patented single-component self-assembling protein nanoparticle (1c-SApNP) platform...

Read More

map
  • 660 W Germantown Pike, Newark, Delaware, 19462, United States Headquarters: 660 W Germantown Pike, Newark, Delaware, 19462, United States
  • 2018 Date Founded: 2018
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $250 Million to $500 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 541714 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from UVAX BIO

Uvax Bio Org Chart and Mapping

Employees

Matthijs Schoots

Chief of Staff, Head Strategic Planning

Cyril Empig

Lead, Non-Clinical Studies

Ke Li

Vice President, Vaccine Development and Technical Ops

Benjamin Wang

Business Development Associate

Kevin O'Neill

Senior Vice President, Corporate Strategy

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Uvax Bio

Answer: Uvax Bio's headquarters are located at 660 W Germantown Pike, Newark, Delaware, 19462, United States

Answer: Uvax Bio's official website is https://uvaxbio.com

Answer: Uvax Bio's revenue is $250 Million to $500 Million

Answer: Uvax Bio's SIC: 2834

Answer: Uvax Bio's NAICS: 541714

Answer: Uvax Bio has 11-50 employees

Answer: Uvax Bio is in Biotechnology

Answer: Uvax Bio contact info: Phone number: Website: https://uvaxbio.com

Answer: Founded in early 2018, Uvax Bio, a spin-off vaccine company from Scripps Research, La Jolla, CA, employs patented single-component self-assembling protein nanoparticle (1c-SApNP) platform technology developed by Professor Jiang Zhu of Scripps Research to develop and commercialize B-cell focused, rapid antibody-eliciting, preventive vaccines for the most challenging diseases around the world. Our 1c-SApNP technology streamlines vaccine development and has delivered promising vaccine candidates to address global health challenges such as HIV, RSV/hMPV, PIV1-5, Ebola/Marburg, Lassa, coronaviruses including SARS-CoV, MERS-CoV and SARS-CoV-2, HCV, ZIKV/DENV, and non-viral diseases such as Malaria and Tuberculosis.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access